Latest On ABIVAX Société Anonyme (AAVXF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-03-18 09:27 EST | News | ABIVAX Société Anonyme reports FY results | N/A |  |
| 2022-01-19 23:16 EST | News | Abivax ABX196 shows benefit in liver cancer patients in phase 1/2 trial | N/A | |
| 2021-12-16 00:57 EST | News | Abivax: Potentially The Next Arena Pharmaceuticals, Most Ideal Big Pharma M&A Target In 2022 | N/A | |
| 2021-07-23 13:29 EST | News | Abivax prices oversubscribed capital increase of €60M and €85M in convertible bonds | N/A | |
| 2021-07-22 16:47 EST | News | Abivax reports strong phase 2 data on ulcerative colitis candidate; shares up 12% | N/A | |
| 2021-04-14 20:05 EST | News | Abivax completes induction treatment in phase 2 ulcerative colitis trial of ABX464 | N/A | |
| 2021-03-07 02:00 EST | News | ABIVAX halts COVID-19 trial after finding lack of efficacy | N/A | |
| 2020-12-04 06:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-03 11:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-27 06:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-25 09:32 EST | News | ABIVAX Société Anonyme reports 1H results | N/A | |
| 2020-09-17 09:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-22 17:43 EST | News | Study of Abivax COVID-19 drug expanded to Brazil | N/A | |
| 2020-06-19 15:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-15 16:56 EST | News | Abivax receives non-dilutive financing | N/A | |
| 2020-06-14 08:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-14 03:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 11:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 09:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 11:08 EST | News | ABIVAX Société Anonyme reports FY results | N/A | |
About ABIVAX Société Anonyme (AAVXF):
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.
General
- Name ABIVAX Société Anonyme
- Symbol AAVXF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 27
- Fiscal Year EndDecember
- Web URLhttp://www.abivax.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 16857.84
- Price/Book (Most Recent Quarter) 47.3
- Enterprise Value Revenue 24466.82
View More
Financials
- Most Recent Quarter 2020-06-30
- Return on Assets -39%
- Return on Equity -209%
- Earnings Per Share -$1.51
- Revenue Per Share $0
- Gross Profit -28186000
- Quarterly Earnings Growth 15%
View More
Highlights
- Market Capitalization 342.34 million
- Book Value Per Share $4.80
View More
Share Statistics
- Shares Outstanding 14.38 million
- Shares Float 5.33 million
- % Held by Insiders 687%
- % Held by Institutions 53.57%
View More
Technicals
- Beta 1.15
- 52 Week High $43.97
- 52 Week Low $13.15
- 50 Day Moving Average 34.51
- 200 Day Moving Average 36.15
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
ABIVAX Société Anonyme (AAVXF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
ABIVAX Société Anonyme (AAVXF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-06-30 | $N/A | -$0.71 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $-20000 | -$0.70 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $-20000 | -$0.76 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $20000 | -$0.74 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $20000 | -$0.79 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $161500 | -$0.78 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $161500 | -$0.48 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $246000 | -$0.49 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $246000 | -$0.42 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $176500 | -$0.45 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $176500 | -$0.34 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $2000 | -$0.34 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $2000 | -$0.33 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $7000 | -$0.30 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $7000 | -$0.33 | $0.00 | |
| 2016-06-30 | 2016-09-30 | -$0.35 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$0.48 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.49 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.49 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$0.51 | -$0.32 | -58.69% | |
| 2015-03-31 | 2015-06-30 | -$0.41 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.40 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.39 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.40 | $0.00 |
ABIVAX Société Anonyme (AAVXF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 14.5 million | 14.5 million | 7.49 million |
| Income Before Tax | N/A | N/A | -8.43 million | -8.43 million | -8.97 million |
| Selling General Administrative | N/A | N/A | 898000 | 898000 | 1.25 million |
| Gross Profit | N/A | N/A | 7.29 million | 7.29 million | -7.29 million |
| Ebit | N/A | N/A | -8.04 million | -8.04 million | -8.61 million |
| Operating Income | N/A | N/A | -8.04 million | -8.04 million | -8.61 million |
| Income Tax Expense | N/A | N/A | -220500 | -220500 | -1.88 million |
| Total Revenue | N/A | N/A | -20000 | -20000 | 20000 |
| Cost of Revenue | N/A | N/A | -7.31 million | -7.31 million | 7.31 million |
| Total Other Income Expense Net | N/A | N/A | -398500 | -398500 | -351500 |
| Net Income From Continuing Operations | N/A | N/A | -8.21 million | -8.21 million | -7.09 million |
| Net Income Applicable to Common Shares | -7.7 million | -7.7 million | -8.21 million | -8.21 million | -7.09 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 1.48 million | 1.48 million | N/A | N/A | 1.75 million |
| Total Cash Flow from Investing Activities | 246500 | 246500 | N/A | N/A | -138500 |
| Net Borrowings | 5.04 million | 5.04 million | N/A | N/A | 5 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | 5.18 million |
| Change to Operating Activities | 1.99 million | 1.99 million | N/A | N/A | 1.35 million |
| Change in Cash | N/A | N/A | N/A | N/A | -723000 |
| Total Cash from Operating Activities | -4.17 million | -4.17 million | N/A | N/A | -5.76 million |
| Depreciation | N/A | N/A | N/A | N/A | 22500 |
| Other Cash Flow from Investing Activities | 204500 | 204500 | N/A | N/A | 13000 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | -33000 |
| Other Cash Flow from Financing Activities | -500 | -500 | N/A | N/A | -25000 |
| Change to Net Income | 55000 | 55000 | N/A | N/A | -1.77 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | 284000 |
Balance Sheet:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 33.69 million |
| Total Stockholder Equity | N/A | N/A | N/A | 20.91 million | 20.91 million |
| Other Current Liabilities | 2.22 million | N/A | N/A | N/A | 1.73 million |
| Total Assets | N/A | N/A | N/A | N/A | 54.6 million |
| Common Stock | 122000 | N/A | N/A | N/A | 103000 |
| Other Current Assets | 207000 | N/A | N/A | N/A | 1.44 million |
| Retained Earnings | -15.42 million | N/A | N/A | N/A | -76.57 million |
| Other Liabilities | 1000 | N/A | N/A | N/A | N/A |
| Other Assets | 926000 | N/A | N/A | N/A | 1000 |
| Cash | N/A | N/A | N/A | N/A | 11.56 million |
| Total Current Liabilities | 20.01 million | N/A | N/A | N/A | 29.69 million |
| Other Stockholder Equity | 13.48 million | N/A | N/A | N/A | 6.22 million |
| Property, Plant & Equipment | 104000 | N/A | N/A | N/A | 163000 |
| Total Current Assets | 16.69 million | N/A | N/A | N/A | 21.29 million |
| Long Term Investments | N/A | N/A | N/A | N/A | 1.14 million |
| Net Tangible Assets | -22.49 million | -13.5 million | N/A | -11.09 million | -11.09 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 6000 |
| Long Term Debt | N/A | N/A | N/A | N/A | 4 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 13.51 million | N/A | N/A | N/A | 10.16 million |
ABIVAX Société Anonyme (AAVXF) Chart:
ABIVAX Société Anonyme (AAVXF) News:
Below you will find a list of latest news for ABIVAX Société Anonyme (AAVXF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ABIVAX Société Anonyme (AAVXF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
ABIVAX Société Anonyme (AAVXF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|